Loading…
← CockpitCompetitor Analysis › 445680.KS Curiox Biosystems Co., Ltd.Open in the cockpit ↗

Curiox Biosystems Co., Ltd.445680.KSCompetitor analysis, valuation and peers

South Korea · KRW·Information Technology›Packaged Software
Momentum neutral 51
Mkt cap
$577M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$9.27M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.9 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Close · KRW₩45,500
1D-6.9%
1W-7.9%
1M-23.1%
3M+8.5%
6M-55.4%
YTD-61.1%
1Y-34.6%
ATR %14.1%
52w lowhigh69.5% off high

What Curiox Biosystems does

Employees: 22

Curiox Biosystems at a glance

Size Curiox Biosystems (445680.KS) is a South Korea Information Technology company (Packaged Software) with a market value of $577M, the 311th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩45,500 on 6 Nov 2026.

Performance Over six months the shares fell 55.4%, against -20.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 19 in its peer set.

Growth Revenue grew 37.2% over the last twelve months (peer median +8.0%); the operating margin is -244.8% (peer median -6.4%).

Valuation It trades at 134.2× enterprise value to sales against a peer median of 4.1× (most expensive of 20).

Capital Return on invested capital runs 27.9 points below its cost of capital (7.9% WACC).

Relative performance

40608010011 May 202611 Aug 20266 Nov 2026Peer median 77445680.KS 45
Six months, rebased to 100: Curiox Biosystems against the median of its 20 peers (local-currency closes).

Curiox Biosystems financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩5.84B₩5.15B₩4.59B₩6.79B₩7.24B
Revenue growth—+12%-32%-6%—
Gross profitn/a₩401M₩783M₩2.20B₩3.31B
EBITDAn/a-₩10.1B-₩11.3B-₩8.61B-₩9.82B
Net income-₩15.1B-₩27.2B-₩8.09B-₩10.0B-₩11.5B
Free cash flown/a-₩11.2B-₩9.96B-₩8.38B-₩10.8B
Capital expendituren/a₩136M₩258M₩212M₩841M
Total debtn/a₩2.45B₩8.14B₩965M₩387M

Quarterly statements and history in the cockpit →

Curiox Biosystems competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-100%-50%0%-50%-25%0%0021483005180068688489002912603258600212QDTCGNTATOSTYL6687RZLVSOPH688039445680.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Curiox Biosystems is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×50×100×0021483005180068688489GNSRZLV445680.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Curiox Biosystems is the large dot.

Curiox Biosystems competitors and peer comparison

How Curiox Biosystems compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Curiox Biosystems against its 20 peers (data as of 6 Nov 2026)
Measure445680.KSPeer medianRank in peer set
1-month return-23.1%-8.7%4th lowest of 20
6-month return-55.4%-20.8%2nd lowest of 19
Distance from 52-week high-69.5%-36.4%3rd lowest of 20
Revenue growth (TTM)+37.2%+8.0%4th highest of 21
Operating margin-244.8%-6.4%lowest of 21
EV / Sales134.2×4.1×most expensive of 20
ROIC minus cost of capital-27.9 pp-11.6 pp6th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Curiox Biosystems 445680.KSSouth Korea$577M-55%+37%-245%134.2×n/an/a
Beijing Bewinner Communications 002148.SZChina$573M-25%+5%-3%9.1×n/an/a
Elice 0158S0.KSSouth Korea$572Mn/a+14%14%n/an/an/a
Guangxi Xinxunda Technology 300518.SZChina$571M-20%-35%-105%31.5×n/an/a
Manycore Tech 0068.HKHong Kong$567M-90%+9%0%3.0×n/an/a
Sansec Technology 688489.SSChina$590M-13%+18%-7%5.5×n/an/a
Shenzhen Sinovatio Technology 002912.SZChina$592M-2%+7%-10%4.1×n/an/a
Hangzhou Electronic Soul Network Technology 603258.SSChina$562M-7%-9%-79%6.9×n/an/a
UISEE Technologies (Beijing) 1511.HKHong Kong$593Mn/a+24%-71%11.2×n/an/a
Gresgying Digital Energy Technology 600212.SSChina$594M-34%-8%-6%3.3×23.5%+38.2%
Quadient QDT.PAFrance$560M+24%-10%12%1.2×-2.4%+0.1%
ENC Digital Technology 603869.SSChina$559M-26%-10%-8%4.1×n/an/a
Cognyte Software CGNTUnited States$597M-27%+28%5%1.3×22.2%-2.0%
Niewiadow Polish Military Group Joint Stock GNS.WAPoland$557M-22%+490%-73%23.7×n/an/a
Atos ATO.PAFrance$555M-35%-14%6%0.3×n/an/a
Seshaasai Technologies STYL.NSIndia$554M+20%-2%23%3.2×12.2%+7.9%
PKSHA Technology 3993.TJapan$602M-8%+74%16%2.5×16.6%+24.1%
JST 6687.HKHong Kong$603M-28%+26%11%1.1×-11.9%+30.3%
Rezolve AI RZLVUnited States$550M-45%+2,224%-94%3.6×n/an/a
Sophia Genetics SOPHUnited States$608M+39%+24%-80%6.3×n/an/a
Hangzhou Arcvideo Technology 688039.SSChina$609M-13%+1%-48%12.5×n/an/a

Questions

Which companies are Curiox Biosystems's closest peers?
The cockpit's peer set: Beijing Bewinner Communications (002148.SZ), Elice (0158S0.KS), Guangxi Xinxunda Technology (300518.SZ), Manycore Tech (0068.HK), Sansec Technology (688489.SS), Shenzhen Sinovatio Technology (002912.SZ), Hangzhou Electronic Soul Network Technology (603258.SS), UISEE Technologies (Beijing) (1511.HK).
Is Curiox Biosystems expensive compared with its peers?
On ev / sales it trades at 134.2× against a peer median of 4.1×, most expensive of 20 in its peer set.
How has Curiox Biosystems stock performed?
Over six months to 6 Nov 2026 the shares returned -55.4% against -20.8% for the median peer; over one year -34.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.